Kimberly Manhard Heron Therapeutics, Inc. (HRTX) insider trading activity

Kimberly Manhard is EVP, Drug Development of HERON THERAPEUTICS, INC. . Currently has a direct ownership of 28,330 shares of HRTX, which is worth approximately $44,761. The most recent transaction as insider was on Apr 13, 2023, when has been sold 1,417 shares (Common Stock) at a price of $2.88 per share, resulting in proceeds of $4,080. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 28.3K

0% 3M change

0% 12M change

Total Value Held $44,761

KIMBERLY MANHARD Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 13 2023	SELL Payment of exercise price or tax liability	$4,080 $2.88 p/Share	1,417 Reduced 4.76%	28,330 Common Stock
Apr 13 2023	BUY Exercise of conversion of derivative security	-	5,814 Added 16.35%	29,747 Common Stock
Jan 13 2023	SELL Payment of exercise price or tax liability	$6,378 $3.17 p/Share	2,012 Reduced 7.75%	23,933 Common Stock
Jan 13 2023	BUY Exercise of conversion of derivative security	-	5,814 Added 18.31%	25,945 Common Stock
Oct 31 2022	BUY Other acquisition or disposition	$5,411 $3.27 p/Share	1,655 Added 7.6%	20,131 Common Stock
Oct 13 2022	SELL Payment of exercise price or tax liability	$7,565 $3.76 p/Share	2,012 Reduced 9.82%	18,476 Common Stock
Oct 13 2022	BUY Exercise of conversion of derivative security	-	5,814 Added 22.1%	20,488 Common Stock
Jul 13 2022	SELL Payment of exercise price or tax liability	$6,056 $3.01 p/Share	2,012 Reduced 12.06%	14,674 Common Stock
Jul 13 2022	BUY Exercise of conversion of derivative security	-	5,814 Added 25.84%	16,686 Common Stock
May 03 2022	SELL Open market or private sale	$7,159 $4.76 p/Share	1,504 Reduced 12.15%	10,872 Common Stock
Apr 29 2022	BUY Other acquisition or disposition	$5,775 $3.84 p/Share	1,504 Added 10.84%	12,376 Common Stock
Apr 13 2022	SELL Payment of exercise price or tax liability	$12,213 $6.07 p/Share	2,012 Reduced 15.62%	10,872 Common Stock
Apr 13 2022	BUY Exercise of conversion of derivative security	-	5,814 Added 31.09%	12,884 Common Stock
Jan 13 2022	SELL Payment of exercise price or tax liability	$16,700 $8.3 p/Share	2,012 Reduced 22.15%	7,070 Common Stock
Jan 13 2022	BUY Exercise of conversion of derivative security	-	5,814 Added 39.03%	9,082 Common Stock
Oct 13 2021	SELL Payment of exercise price or tax liability	$4,568 $10.55 p/Share	433 Reduced 11.7%	3,268 Common Stock
Oct 13 2021	BUY Exercise of conversion of derivative security	-	1,250 Added 25.25%	3,701 Common Stock
Jul 13 2021	SELL Payment of exercise price or tax liability	$5,837 $13.48 p/Share	433 Reduced 15.01%	2,451 Common Stock
Jul 13 2021	BUY Exercise of conversion of derivative security	-	1,250 Added 30.24%	2,884 Common Stock
May 03 2021	SELL Open market or private sale	$27,002 $17.66 p/Share	1,529 Reduced 48.34%	1,634 Common Stock
Apr 30 2021	BUY Other acquisition or disposition	$21,253 $13.9 p/Share	1,529 Added 32.59%	3,163 Common Stock
Apr 13 2021	SELL Payment of exercise price or tax liability	$7,214 $16.66 p/Share	433 Reduced 20.95%	1,634 Common Stock
Apr 13 2021	BUY Exercise of conversion of derivative security	-	1,250 Added 37.68%	2,067 Common Stock
Jan 13 2021	SELL Payment of exercise price or tax liability	$7,863 $18.16 p/Share	433 Reduced 34.64%	817 Common Stock
Jan 13 2021	BUY Exercise of conversion of derivative security	-	1,250 Added 50.0%	1,250 Common Stock

Also insider at

INBX

Inhibrx, Inc. Healthcare

Director

INXB

Inhibrx Biosciences, Inc.

Director